Amicus Therapeutics, Inc.

FOLDNASDAQHealthcare

$14.49

+$0.00(+0.00%)

Market Cap$4.5B

P/E Ratio—

52W High$14.5

52W Low$5.51

Avg Volume4.2M

Open$14.49

Beta0.48

Free Cash Flow Financials Revenue

Amicus Therapeutics, Inc. (FOLD) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

FOLD · free cash flow · updated Jun 8, 2026

Core FCF metrics

FOLD · FCF · TTM · margin & CAGR

Free cash flow was $29.8M for FY2025 (fiscal year ending 2025-12-31), up 179.7% year-over-year The FCF margin was 4.7%.

FY2025 Free Cash Flow$29.8M▲ +179.7% YoY

Trailing 12M (TTM)$29.8Mtrailing 4 quarters sum

FCF Margin4.7%$29.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

FOLD · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$33.1M(3M)$29.8M▲ +179.7%4.7%

FY2024−$33.9M(4M)−$37.4M▲ +51.1%-7.1%

FY2023−$69.1M(7M)−$76.5M▲ +55.1%-19.2%

FY2022−$166.6M(4M)−$170.3M▲ +17.5%-51.7%

FY2021−$202.5M(4M)−$206.4M▲ +12.7%-67.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

FOLD · P/FCF · FCF yield · FCF per share

Amicus Therapeutics, Inc. (FOLD) trades at a FCF yield of 0.66% and a price-to-free-cash-flow ratio of 144.9x. FCF per share stands at $0.10, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

0.66%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.10

TTM FCF ÷ Shares Outstanding

Price / FCF

x144.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x161.4

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

FOLD · cash flow statement · operating / investing / financing

For FY2025, Amicus Therapeutics, Inc. generated $33.1M in operating cash flow and spent 3M in capital expenditures, yielding $29.8M in free cash flow.

Operating Activities

+$33.1M

Cash from core business operations

2025-12-31

Investing Activities

−$46.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$0.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($33.1M) − |CapEx| (3M) = FCF ($29.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

FOLD vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Amicus Therapeutics, Inc.YOU

FOLD

$29.8M+179.7%4.7%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Amicus Therapeutics, Inc. (FOLD) reported free cash flow of $29.8M for FY2025 (fiscal year ending 2025-12-31), up 179.7% year-over-year. The FCF margin was 4.7%.

Based on available data, Amicus Therapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $29.8M in FY2025.

Amicus Therapeutics, Inc.'s FCF yield is 0.66% and price-to-FCF ratio is 144.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

FOLD free cash flow · 8 questions

Amicus Therapeutics, Inc. free cash flow was $29.8M for FY2025, up 179.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $29.8M.

FOLD free cash flowFOLD FCFFOLD FCF 2025FOLD free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Amicus Therapeutics, Inc. · Amicus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026